Navigation Links
AIDS expert says global strategy needed to combat feminization of HIV/AIDS

sub-Saharan Africa, are female, Quinn says, and in South Africa, Zambia and Zimbabwe, young women ages 15 to 24 are three to six times more likely to be infected than men. Women make up half the adult population living with the virus in the Caribbean and one-third of those in Latin America.

The reasons for the rise in female cases differ among countries, with 97 percent of female HIV infections in the United States due to heterosexual transmission (81 percent) and intravenous drug use (16 percent). In the developing world, heterosexual transmission is responsible for nearly all of the infections among women, and mother-to-child transmission during childbirth further contributes to the spread of the disease.

Women are particularly vulnerable to such cultural factors as their relative lack of power in sexual relationships, widespread poverty, policies that deny women an education and tolerance of violence against women.

The excessive biological vulnerability to HIV among young women, is believed to be due to an immature genital whose mucosal lining is easier for the virus to penetrate; to hormonal factors, such as the use of birth control pills; and to a high incidence of sexually transmitted diseases, which inflame the female genital area and provide additional target cells for the virus to infect.

Quinn says that eventually societal changes will help, but immediate and faster action requires coordinated efforts to focus on women, develop effective microbicides that women can use themselves and a gender-specific vaccine program that takes into account the different immune responses between women and men.

Cultural programs are also needed for reshaping gender roles, such as educating more women about safe-sex practices, use of condoms, lessons on negotiating safe sex, and awareness campaigns about where to seek testing and treatment.

Quinn says that women are different when it comes to HIV infection, and if medical progr
'"/>

Source:News-Medical Net


Page: 1 2 3

Related biology news :

1. South Americas vast pantanal wetland may become next everglades, UNU experts warn
2. Hopkins AIDS experts issue warning about global efforts to provide drug therapies
3. Crisis in African fish supplies looms, experts warn Africa leaders
4. Infectious disease expert warns of spread of Rocky Mountain spotted fever
5. Tsunami + 1 year: Reviving exhausted fisheries should trump replacing boats, gear, experts say
6. Johns Hopkins flu expert calls for mandatory vaccination of health care workers
7. Evidence for omega 3 fats less conclusive than we thought, say experts
8. Medical experts: US unlikely to have enough vaccines to stop avian flu
9. Deep-rooted plants have much greater impact on climate than experts thought
10. Climate experts search for answers in the oceans
11. Comments, experts and background on the 2006 Nobel Prize in chemistry
Post Your Comments:
Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6